Concise Communication

Impact of rapid Cepheid Xpert Xpress severe acute respiratory coronavirus virus 2 (SARS-CoV-2) reverse-transcription polymerase chain reaction (RT-PCR) testing in Detroit Medical Center hospitals during the coronavirus disease 2019 (COVID-19) pandemic

Monica P. Meyer MS, MPH^1, Jennifer LeRose MPH^2, Catherine Maples^1 and Teena Chopra MD, MPH^1,3

^1Wayne State University School of Medicine, Detroit, Michigan, ^2Michigan State University, College of Osteopathic Medicine, East Lansing, Michigan and ^3Division of Infectious Disease, Department of Internal Medicine, Detroit Medical Center, Detroit, Michigan

Abstract

In March 2020, the coronavirus disease 2019 (COVID-19) pandemic raged, and samples from the Detroit Medical Center (DMC) were sent offsite for testing. From April 3, 2020, DMC laboratories ran rapid Cepheid Xpert Xpress severe acute respiratory coronavirus virus 2 (SARS-CoV-2) reverse-transcription polymerase chain reaction (RT-PCR) tests within hospital labs. We detected differences in length of stay (LOS) and antibiotic duration between positive results from offsite and in-house tests.

Numerous cases of pneumonia of unknown origin were detected in China in December 2019. These cases were quickly linked to the novel virus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) cases rapidly spread worldwide and officially became a global pandemic in March 2020. To date, >89 million cases of COVID-19 in the United States have been confirmed as well as >1 million associated deaths.

Detroit, Michigan, was especially affected by the pandemic, ranking third in the country for confirmed cases during March and April 2020. The first case of COVID-19 in Michigan was detected at the Detroit Medical Center (DMC) on March 11, 2020. Initially, nasopharyngeal swab samples were sent to outside laboratories, and the turnaround time was ∼7–10 days. As the DMC became flooded with cases through March and into early April, this offsite testing turnaround time became increasingly untenable.

As COVID-19 cases continued to increase in Detroit, timely and accurate SARS-CoV-2 laboratory testing became an essential part of the management of COVID-19 because it helped to identify and contain viral spread. Supporting decisions on infection control strategies, patient management at healthcare facilities, and detecting asymptomatic cases that could cause further spread if not isolated are also benefits of timely testing. The rapid Cepheid Xpert Xpress SARS-CoV-2 reverse-transcription polymerase chain reaction (RT-PCR) test (Cepheid, Sunnyvale, CA) was implemented and run in house at the DMC on April 3, 2020. This test provided a faster turnaround time than offsite testing. In this study, we compared hospital length of stay (LOS) and duration of antibiotics between SARS-CoV-2–positive COVID-19 patients who underwent testing via Cepheid Xpert Xpress PCR performed at DMC and those who did not (ie, samples were sent to external laboratories).

Methods

We performed a descriptive study using the DMC COVID-19 patient registry. The patient registry was developed by the Wayne State University Organized Research Consortium to Study COVID-19 (WORCS-C) through medical record extraction by trained healthcare staff. Patients included in the registry were all SARS-CoV-2–positive COVID-19 cases identified at a DMC institution between March 11, 2020, and May 14, 2020. Institutional review board approval was obtained.

Length of stay

The distribution of LOS was compared between groups as hours, days, and log transformed LOS, as well as with emergency department (ED) and inpatient stratifications. Generalized linear mixed models were used to test for differences in LOS with adjustment for patient-level characteristics. Post hoc analyses modeled median differences with quantile regression to account for skewness. Results were not appreciably different and thus are not reported.

© The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Antibiotic duration

General linear models were fit to determine whether the mean number of days on antibiotic treatment differed among patients who tested positive for SARS-CoV-2 using either a Cepheid test or an alternative.

Results

Among the 1,473 COVID-19 patients included in the study, 925 (63%) received offsite SARS-CoV-2 testing (March 11–April 3, 2020) and 548 (37%) received Cepheid Xpert Xpress SARS-CoV-2 PCR testing (April 3–May 14, 2020). The offsite testing group was 53% male; 70% were aged 60 years and older; 59% were African American, and 33% were obese (Table 1).

Without adjustment for patient-level characteristics, the LOS was significantly greater in the Cepheid-test study group than among patients whose nasopharyngeal swabs were tested by external laboratories: LOS median, 6.9 days (interquartile range [IQR], 2–14) versus 5.3 days (IQR, 2–10) and least squares mean log 2 (LOS), 2.7 versus 2.5 days \((P = .01)\). The LOS remained significantly elevated among patients who were tested using the Cepheid test after adjusting for age and race categories, the total number of clinical diagnoses (an indicator of case-mix severity) and obesity: least squares mean log 2 (LOS), 2.4 versus 2.2 days \((P = .02)\).

In contrast to total LOS, the emergency department (ED) LOS was lower in the Cepheid-test study group compared to patients whose nasal swabs were tested by external laboratories: the ED LOS median was 26 (IQR, 4–21) versus 36 hours (IQR, 2–10), the least-squares mean log 2 (LOS) was 0.7 versus 1.0 days \((P = .01)\), and the adjusted mean log 2 (LOS) was 0.4 versus 0.7 days \((P < .0001)\) (Fig. 1).

### Table 1. Descriptive Characteristics of Patient Encounters by Test Type

| Characteristic                  | Offsite Test \((n = 925)\) | Cepheid Rapid PCR \((n = 548)\) | Overall \((n = 1,473)\) |
|-------------------------------|------------------------------|----------------------------------|-------------------------|
|                               | No.  | %    | No.  | %    | No.  | %    |
| Sex                           |      |      |      |      |      |      |
| Female                        | 452  | 48.9 | 257  | 46.9 | 709  | 48.1 |
| Male                          | 473  | 51.1 | 290  | 52.9 | 763  | 51.8 |
| Unknown                       | 0    |      | 1    | 0.2  | 1    | 0.1  |
| Age groups                    |      |      |      |      |      |      |
| 0–4 y                         | 5    | 0.5  | 6    | 1.1  | 11   | 0.7  |
| 5–17 y                        | 4    | 0.4  | 4    | 0.7  | 8    | 0.5  |
| 18–24 y                       | 5    | 0.5  | 6    | 1.1  | 11   | 0.7  |
| 25–39 y                       | 67   | 7.2  | 37   | 6.8  | 104  | 7.1  |
| 40–49 y                       | 102  | 11.0 | 36   | 6.6  | 138  | 9.4  |
| 50–59 y                       | 155  | 16.8 | 77   | 14.1 | 232  | 15.8 |
| 60–69 y                       | 250  | 27.0 | 144  | 26.3 | 394  | 26.7 |
| 70–79 y                       | 196  | 21.2 | 135  | 24.6 | 331  | 22.5 |
| ≥80 y                         | 141  | 15.2 | 103  | 18.8 | 244  | 16.6 |
| Race                          |      |      |      |      |      |      |
| Black                         | 562  | 60.8 | 325  | 59.3 | 887  | 60.2 |
| Other/Unknown                 | 322  | 34.8 | 179  | 32.7 | 501  | 34.0 |
| White                         | 41   | 4.4  | 44   | 8.0  | 85   | 5.8  |
| BMI                           |      |      |      |      |      |      |
| Class I obesity               | 162  | 17.5 | 81   | 14.8 | 243  | 16.5 |
| Class II obesity              | 115  | 12.4 | 52   | 9.5  | 167  | 11.3 |
| Class III obesity             | 141  | 15.2 | 48   | 8.8  | 189  | 12.8 |
| Not documented                | 111  | 12.0 | 87   | 15.9 | 198  | 13.4 |
| Overweight                    | 219  | 23.7 | 123  | 22.4 | 342  | 23.2 |
| Underweight                   | 21   | 2.3  | 25   | 4.6  | 46   | 3.1  |
| Z-normal weight               | 156  | 16.9 | 132  | 24.1 | 288  | 19.6 |
| Smoking status                |      |      |      |      |      |      |
| Nonsmoker                     | 844  | 91.2 | 492  | 89.8 | 1,336| 90.7 |
| Regular smoker                 | 81   | 8.8  | 56   | 10.2 | 137  | 9.3  |

Note. PCR, polymerase chain reaction assay; BMI, body mass index.
Overall, the average number of days on antibiotic treatment differed significantly between patients who did and did not test positive for SARS-CoV-2 by the Cepheid test depending on their age group (interaction $P = .003$) and adjusting for potentially confounding factors (ie, race category and the sum of clinical diagnoses).

Children (aged <18 years) who were identified by the Cepheid test received antibiotics for 3 fewer days than their same-age peers who were not identified by the Cepheid test ($P = .01$). By contrast, patients aged 50–64 years received antibiotics for 2.7 more days than their peers of the same age who were detected by an alternative test ($P = .03$). We did not detect differences in the duration of antibiotics treatment by test type among patients aged 18–49 years (difference, 1 day; $P = .41$) or ≥65 years (difference, 0.9 day; $P = .06$).

**Discussion**

Our study has demonstrated multiple benefits that correlate with shorter test-turnaround time provided by the Cepheid Xpert Xpress SARS-CoV-2 rapid PCR that was run in house. First, the data show shorter LOS for ED patients within the in-house cohort. We suspect that readily available SARS-CoV-2 laboratory results allowed clinicians to create more accurate treatment plans and to swiftly discharge patients who were confirmed SARS-CoV-2 negative by the Cepheid test. The Cepheid test results also likely allowed for quicker implementation of isolation precautions for patients that tested positive, helping to curb the spread of the virus.

Interestingly, the LOS for admitted COVID-19 patients was greater within the Cepheid test cohort. We suspect that this seemingly counterintuitive finding can be explained as follows. (1) Better treatment options for COVID-19 treatment became available as the pandemic progressed, such as dexamethasone in severely ill patients, increasing survival which in turn prolonged LOS. (2) Public awareness surrounding COVID-19 infection increased; thus, patients likely sought medical treatment earlier in their disease course. And (3) positive SARS-CoV-2 PCR results may have expedited admission orders for COVID-19 patients.4

Additionally, Cepheid testing was correlated with shorter duration of antibiotic therapy for select patient populations. Pneumonia caused by SARS-CoV-2 virus mimics bacterial pneumonia; both have constitutional and respiratory symptoms. However, antibiotics are not indicated for the treatment of COVID-19 pneumonia.4 Therefore, we suspect that clinicians initiated antibiotics for presumptive bacterial pneumonia upon patient arrival and stopped antibiotic therapy upon notification of positive SARS-CoV-2 PCR results. Consequently, the faster turnaround time provided by the Cepheid testing allowed for reduced antibiotic administration.

Our study had several limitations. First, DMC is an urban teaching hospital with a unique patient population; thus, our results may not be generalizable to rural hospitals. Additionally, we did not examine potentially confounding factors related to the pandemic, such as personal protective equipment shortages and changes in triage procedures, due to the inability to retroactively quantify these variables. Nevertheless, we were able to demonstrate statistically significant differences between cohorts regarding LOS and antibiotic usage.

These data provide preliminary evidence to support the use of Cepheid Xpert Xpress SARS-CoV-2 PCR testing in hospitals. The benefits include decreased ED LOS and antibiotic usage. Both factors are essential in minimizing resource exhaustion and containing the continued spread of the SARS-CoV-2 virus. Further research with larger studies that address confounding factors is needed to understand this correlation.
Acknowledgments. The authors acknowledge all individuals who performed testing and care during the COVID-19 pandemic.

Financial support. This study was financially supported by Cepheid.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References

1. What is coronavirus? Johns Hopkins Medicine website. https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus. Published 2020. Accessed May 15, 2020.

2. COVID data tracker. Center for Disease Control and Prevention website. https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Published 2021. Accessed July 20, 2022.

3. After surge in cases, Michigan now 3rd in country for coronavirus deaths. NPR Coronavirus Updates. National Public Radio website. https://www.npr.org/sections/coronavirus-live-updates/2020/03/31/824738996/after-surge-in-cases-michigan-now-3rd-in-country-for-coronavirus-deaths. Accessed July 6, 2021.

4. IDSA guidelines on the treatment and management of patients with COVID-19. Infectious Diseases Society of America website. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Published 2020. Accessed November 21, 2021.